Fig. 2.
Male 12-week-old NOD scid gamma mouse mice were injected subcutaneously into the left flank with 1 × 106NTAL–KD cells and received an equal number of CT (shRNA negative control) cells in the right flank.A, sections of U937 (CT and NTAL–KD) tumors stained with hematoxylin and eosin or immunostained for NTAL. B, tumor masses derived after 2 weeks: U937: CT (1.073 g ± 0.1486) and NTAL–KD (0.5975 g ± 0.1506) (n = 4, p = 0.0287, 95% confidence interval) and NB4: CT (1.286 g ± 0.3137) and NTAL–KD (0.8540 g ± 0.3402) (n = 5, p = 0.0143, 95% confidence interval) (∗data published) (9). C, Western blotting analysis of total tumor protein extracts from engrafted tumors for NTAL, procaspase-3, p-Akt (Ser-473), Akt, Ras, p-p44/42 MAPK, and p44/42 MAPK (animals A1 = 1, A2 = 2, and A3 = 3). 30 μg of tumor total extract were loaded in each gel lane. CT, control; KD, knockdown; MAPK, mitogen-activated protein kinase; NTAL, non–T cell activation linker.